The progress toward value-based care transformation in oncology was material in 2022. In this report, we examine these advances and what they mean for the coming year. We anticipate that oncology capital investment will increase in 2023, despite macroeconomic conditions.
We provide projections for where the industry is headed in 3 key areas:
- Second-generation alternative payment models (APMs).
- The payvider oncology evolution.
- Digital and home-based value enablement.
“We expect tailwinds for value-based oncology care to gain strength in 2023, supporting continued APM experimentation from payers, alignment of new payvider models, and maturation of digital enablement and home-based care.”
